Adial Pharmaceuticals
ADIL
12 hedge funds and large institutions have $196K invested in Adial Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
1.4% less ownership
Funds ownership: 4.46% → 3.06% (-1.4%)
20% less funds holding
Funds holding: 15 → 12 (-3)
63% less capital inflows, than outflows
Capital inflows: $57.9K | Capital outflows: $157K
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Securities
New York
|
+$28.3K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$20.4K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$8.89K |
| 4 |
Morgan Stanley
New York
|
+$261 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$82.6K |
| 2 |
Renaissance Technologies
New York
|
-$39.5K |
| 3 |
HRT Financial
New York
|
-$33K |
| 4 |
Tower Research Capital (TRC)
New York
|
-$1.75K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$678 |
ADIL Hedge Fund Activity: Q3 2024 in Review
12 of the 6,985 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q3 2024, worth a combined $196K — down 40% from $328K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ADIL and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Two Sigma Securities, opening a new position worth an estimated $28.3K. The largest seller was UBS Group, cutting an estimated $82.6K.
- 12 institutional investors held Adial Pharmaceuticals (ADIL) as of Q3 2024, down from 15 in Q2 2024.
- Funds reported $196K of Adial Pharmaceuticals stock for Q3 2024, down 40% quarter-over-quarter.
- 1 fund opened new Adial Pharmaceuticals positions in Q3 2024 and 3 closed out, a net change of -2 holders.
- The largest Adial Pharmaceuticals buyer in Q3 2024 was Two Sigma Securities, an estimated $28.3K added.
- The largest Adial Pharmaceuticals seller in Q3 2024 was UBS Group, an estimated $82.6K sold.
Based on aggregated 13F filings for Q3 2024.